Key Highlights

● Insmed closed at $144.46 after a Volatility halt.

● An unconfirmed report said Sanofi is evaluating an acquisition.

● No deal has been agreed and neither company commented.

● Insmed was valued at about $31 billion after the rally.

Insmed (NASDAQ:INSM) shares surged on Thursday, November 19, briefly triggering a volatility halt, after a media report said Sanofi (NASDAQ:SNY) is studying a possible Acquisition of the lung-disease drugmaker, though no deal has been agreed and neither company commented.

The report that moved the stock

The trigger was a media report citing people familiar with the matter. According to the report, which was unconfirmed, French drugmaker Sanofi is working with advisers as it evaluates a potential Takeover of Insmed. Talks are ongoing, a deal could be weeks away, and there is no assurance one will happen. Other bidders could also emerge. Neither company commented, and no price or terms were reported.

That was enough to set off a rush of buying. Insmed closed at $144.46, in what was described as its best day since early August. Trading was briefly halted for volatility as the stock spiked. After the rally, Insmed was valued at about $31 billion.

Sanofi's American depositary shares moved the other way, slipping on the day. It is common for a potential acquirer's shares to fall on reports of a large deal, as investors weigh the price it may pay.

Sanofi's stated priorities

Insmed develops treatments for serious and rare lung diseases. Sanofi's own public comments offer some context for the reported interest, though the company has not commented on Insmed. On the company's October earnings call, CEO Belén Garijo said Sanofi would focus its M&A on "our three therapeutic areas, namely immunology, rare diseases, and vaccines."

One commentator wrote that a deal "could rank among the largest biopharmaceutical acquisitions in years."

The report also landed after a difficult stretch for Insmed's stock, which had fallen sharply over the prior 12 months. A report of takeover interest after a long decline can trigger especially sharp moves, because traders start to price in the possibility of a takeover premium over a share price that had been depressed.

A lone bright spot in health care

Insmed's surge stood out in a sector that had a rough day. Health care was among the weaker S&P groups, weighed down by managed-care stocks that continued to fall after the Centers for Medicare & Medicaid Services proposed widening Medicare Advantage audits. UnitedHealth (NYSE:UNH) was among the Dow's biggest decliners.

Other biotech names had mixed news. SELLAS Life Sciences (NASDAQ:SLS) fell after pricing a $150 million stock offering, Celldex Therapeutics (NASDAQ:CLDX) said it would discontinue a drug program in atopic dermatitis after a Phase 2 study missed its Week 16 itch endpoint, and Revolution Medicines (NASDAQ:RVMD) released updated pancreatic cancer data.

The broader market offered no tailwind. The S&P 500 fell 147.80 points to 7,175.83, its sixth straight loss, and the Nasdaq Composite slid 550.69 points to 23,879.20.

What to watch

The key question is whether the report turns into a formal announcement. Until either company speaks, the stock may stay sensitive to any further reports about price, timing or rival bidders. Traders will also watch Sanofi's shares for signs of how its investors view a potential deal. If talks stall, the premium built into Insmed's price on Thursday could be at risk, so headlines in the coming weeks are likely to drive trading in both stocks.